Wave Life Sciences grants director 64,000-share option

Q: What are the exercise price and expiration date of Christian O. Henry's WVE stock option?

The option has an exercise price of $3.75 per share and expires October 5, 2036.

The stock option has an exercise price of $3.75 per share and expires October 5, 2036.

(Neutral)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Wave Life Sciences, Inc. director Christian O. Henry was granted a 10,700-share restricted stock unit award and a stock option covering 64,000 common shares on October 5, 2026. His reported direct common-stock holdings following the RSU award were 23,400 shares. Both awards vest as to 100% of the shares on the earlier of the Company's 2027 annual meeting of stockholders or October 5, 2027.

Insider Trade Summary

Grant/Award: 74,700 shares

Grant/Award 2 txns

Insider HENRY CHRISTIAN O

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy) ^F2	64,000	$0.00	$0.00
Grant/Award	Common Stock ^F1	10,700	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 64,000 contracts (Direct); Common Stock — 23,400 shares (Direct)

Footnotes (2)

F1. The reporting person was granted this restricted stock unit award (RSU) pursuant to the 2026 Non-Employee Director Compensation Policy. The RSU vests as to 100% of the shares on the earlier of the Company's 2027 annual meeting of stockholders or October 5, 2027.
F2. The reporting person was granted this option pursuant to the 2026 Non-Employee Director Compensation Policy. The option vests as to 100% of the shares on the earlier of the Company's 2027 annual meeting of stockholders or October 5, 2027.

Key Figures

Restricted stock unit award: 10,700 shares Stock option award: 64,000 shares Exercise price: $3.75 per share +2 more

5 metrics

Restricted stock unit award 10,700 shares Granted October 5, 2026; scheduled to vest in full

Stock option award 64,000 shares Granted October 5, 2026; scheduled to vest in full

Exercise price $3.75 per share The option expires October 5, 2036

Direct common-stock holdings 23,400 shares Following the October 5, 2026 restricted stock unit award

Vesting schedule 100% Earlier of the 2027 annual meeting of stockholders or October 5, 2027

Key Terms

restricted stock unit award (RSU), Stock Option (right to buy), 2026 Non-Employee Director Compensation Policy

3 terms

restricted stock unit award (RSU) financial

"granted this restricted stock unit award (RSU)"

Stock Option (right to buy) financial

"Stock Option (right to buy)"

2026 Non-Employee Director Compensation Policy financial

"pursuant to the 2026 Non-Employee Director Compensation Policy"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What awards did Christian O. Henry receive in WVE?

On October 5, 2026, director Christian O. Henry was granted a 10,700-share restricted stock unit award and a stock option covering 64,000 common shares; both vest in full on the earlier of the 2027 annual meeting or October 5, 2027.

What are the exercise price and expiration date of Christian O. Henry's WVE stock option?

The option has an exercise price of $3.75 per share and expires October 5, 2036.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Available on EDGAR 10/07/2026 - 09:00 PM Accepted by SEC EDGAR 10/07/2026 - 09:00 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

HENRY CHRISTIAN O

(Last)

(First)

(Middle)

C/O WAVE LIFE SCIENCES, INC.,

733 CONCORD AVE.

(Street)

CAMBRIDGE

MASSACHUSETTS

02138

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Wave Life Sciences, Inc. [ WVE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
10/05/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	10/05/2026		A		10,700⁽¹⁾	A	$0	23,400	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (right to buy)	$3.75	10/05/2026		A		64,000		⁽²⁾	10/05/2036	Common Stock	64,000	$0.00	64,000	D

Explanation of Responses:

1. The reporting person was granted this restricted stock unit award (RSU) pursuant to the 2026 Non-Employee Director Compensation Policy. The RSU vests as to 100% of the shares on the earlier of the Company's 2027 annual meeting of stockholders or October 5, 2027.

2. The reporting person was granted this option pursuant to the 2026 Non-Employee Director Compensation Policy. The option vests as to 100% of the shares on the earlier of the Company's 2027 annual meeting of stockholders or October 5, 2027.

Remarks:

On August 7, 2026, Wave Life Sciences, Inc., a Delaware corporation, became the successor of Wave Life Sciences Ltd., a company organized under the laws of the Republic of Singapore ("Wave-Singapore"), pursuant to a scheme of arrangement under Singapore law under which all issued ordinary shares in the capital of Wave-Singapore were exchanged on a one-for-one basis for shares of common stock of Wave Life Sciences, Inc. (the "Redomiciliation"). The Redomiciliation had the effect of changing Wave-Singapore's domicile, but did not alter the proportionate interests of securityholders. Exhibit 24.1 - Power of Attorney

	/s/ Christian Henry	10/07/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR